Symbiotec Pharmalab Limited Q1 FY27 earnings call summary

Earnings call of 22 Sep 2026, summarised by AI from the filing.

Targeting 20% revenue and 25% EBITDA growth for FY27, plus-minus 5% due to global uncertainties.

Key takeaways

1. Guidance Targeting 20% revenue and 25% EBITDA growth for FY27, plus-minus 5% due to global uncertainties.
2. Change New business expenses now flow through P&L instead of being capitalized, impacting reported profitability.
3. Driver Biotech CDMO contracts (10-year take-or-pay) and complex injectables pipeline to drive future growth.
4. Risk New business revenues depend on customer utilization and capacity expansion timelines; expenses drag continues.

Symbiotec Pharmalab Limited Q1 FY27 results

As filed: Revenue ₹211 cr, EBITDA ₹59.2 cr, PAT ₹47.0 cr, EBITDA margin 28.1%.

Not scored. No result for the same quarter last year.

Symbiotec Pharmalab Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (22 Sep 2026), Results deck (21 Sep 2026)